RhumbLine Advisers
DSCI

RhumbLine Advisers’s Derma Sciences, Inc. Common Stock (DE) DSCI Stock Holding History

RhumbLine Advisers’s Portfolio DSCI Stock Details DSCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-29,174
Closed -$247K – 3221
2015
Q1 		$247K Buy
29,174
+1,500
+5% +$12.8K ﹤0.01% 2723
2014
Q4 		$258K Buy
27,674
+2,600
+10% +$22.6K ﹤0.01% 2667
2014
Q3 		$209K Hold
25,074
– – ﹤0.01% 2727
2014
Q2 		$290K Buy
25,074
+4,190
+20% +$43K ﹤0.01% 2623
2014
Q1 		$265K Buy
20,884
+3,230
+18% +$41.8K ﹤0.01% 2611
2013
Q4 		$191K Sell
17,654
-1,300
-7% -$15.1K ﹤0.01% 2838
2013
Q3 		$235K Sell
18,954
-134
-0.7% -$1.85K ﹤0.01% 2687
2013
Q2 		$255K Buy
+19,088
New +$245K ﹤0.01% 2785

Other funds holding DSCI

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RhumbLine Advisers's DSCI Position: Q2 2015 in Review

RhumbLine Advisers sold out of Derma Sciences, Inc. Common Stock (DE) (DSCI) in Q2 2015, closing a stake of 29,174 shares — an estimated $247K sold.

RhumbLine Advisers first reported a position in DSCI in Q2 2013 and held it in 8 quarters. The position peaked at $290K in Q2 2014. 62 funds tracked by Wall St. Rank hold DSCI as of Q2 2015.

  • RhumbLine Advisers reported no remaining Derma Sciences, Inc. Common Stock (DE) position as of Q2 2015 after selling out during the quarter.
  • RhumbLine Advisers sold 29,174 Derma Sciences, Inc. Common Stock (DE) shares in Q2 2015, an estimated $247K.
  • RhumbLine Advisers first reported a position in Derma Sciences, Inc. Common Stock (DE) in Q2 2013 and held it in 8 quarters.
  • RhumbLine Advisers's Derma Sciences, Inc. Common Stock (DE) position peaked at $290K in Q2 2014.
  • 62 funds tracked by Wall St. Rank held Derma Sciences, Inc. Common Stock (DE) as of Q2 2015.

Based on RhumbLine Advisers's 13F filing for Q2 2015, filed 4 Aug 2015.